Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

The Leukemia-Driving Fusion Protein TCF3–HLF Is Regulated by EP300

DOI: 10.1158/2159-8290.CD-RW2019-176 Published January 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: The histone acetyltransferase EP300 regulates TCF3–HLF, which promotes acute lymphoblastic leukemia.

  • Concept: In TCF3–HLF+ patient-derived xenograft models, an EP300 inhibitor stalled leukemogenesis.

  • Impact: This study provides insight into TCF3–HLF-driven leukemia and identifies a potential vulnerability.

The chimeric transcription factor TCF3–HLF characterizes a subtype of acute lymphoblastic leukemia (ALL) that is highly recalcitrant to treatment. In a study of this cancer-driving fusion protein, Huang, Mouttet, Warnatz, and colleagues first verified that TCF3–HLF is required for disease maintenance in an ALL cell line, a finding they confirmed in two patient-derived xenograft (PDX) mouse models of ALL. Further experiments in an ALL cell line implied that the presence of TCF3–HLF may interfere with transcriptional programs that ordinarily drive lymphoid differentiation and may also increase MYC RNA and MYC protein levels, promoting a stem-like state. In the ALL cells, TCF3–HLF predominantly occupied active enhancers, particularly superenhancers, and notably appeared to target a superenhancer cluster ∼2 Mb downstream of MYC. Chromosome-conformation capture coupled with qPCR in the ALL cell line and the PDX models revealed that TCF3–HLF was required for spatial interactions between the MYC promoter and a pair of superenhancers occupied by the fusion protein. TCF3–HLF colocalized with the proto-oncoprotein ERG on chromatin in ALL cells, including at the previously noted MYC superenhancer, and loss of TCF3–HLF abolished ERG binding at all tested loci, whereas loss of ERG only moderately interfered with TCF3–HLF binding at the same sites, hinting that TCF3–HLF may act as a pioneer transcription factor in this context. Interactome profiling of TCF3–HLF in ALL cells uncovered interactions between the fusion protein and several other transcription factors; of note, there was evidence for interactions between TCF3–HLF and the histone acetyltransferase EP300 as well as some proteins implicated in leukemias and other cancers. In the PDX models, treatment with the EP300 inhibitor A-485 substantially reduced TCF3–HLF RNA levels, decreased the expression of genes activated by TCF3–HLF, and stalled leukemogenesis. Together, these results provide a detailed characterization of TCF3–HLF+ ALL and identify EP300 as a potentially targetable vulnerability in this fatal subtype of leukemia.

Huang Y, Mouttet B, Warnatz HJ, Risch T, Rietmann F, Frommelt F, et al. The leukemogenic TCF3-HLF complex rewires enhancers driving cellular identity and self-renewal conferring EP300 vulnerability. Cancer Cell 2019;36:630–44.e9.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (1)
January 2020
Volume 10, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Leukemia-Driving Fusion Protein TCF3–HLF Is Regulated by EP300
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Leukemia-Driving Fusion Protein TCF3–HLF Is Regulated by EP300
Cancer Discov January 1 2020 (10) (1) 12; DOI: 10.1158/2159-8290.CD-RW2019-176

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Leukemia-Driving Fusion Protein TCF3–HLF Is Regulated by EP300
Cancer Discov January 1 2020 (10) (1) 12; DOI: 10.1158/2159-8290.CD-RW2019-176
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Oncogenes

  • Transposable Elements Regulate Oncogene Expression in Human Cancers
  • KRASG12D Promotes Immunosuppression in Colorectal Cancer
Show more Oncogenes
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement